The patients included in that study all had operable lung cancers, and the investigators used a TheraScreen EGFR mutation kit (DxS, Manchester, UK) to detect 28 specific mutations; some samples were further analyzed by denaturing high-performance liquid chromatography and sequencing. The gene discussed is EGFR; the disease is lung cancer.